Cancer Research Excellence Program

Program Overview

The application process for CREP begins with applicants submitting a short (~6 minutes) RESEARCH PROPOSAL FORM online.
Entries will be accepted from February 14, 2023, until 11:59pm EST*, April 30, 2023.
The Sysmex Inostics, Inc. Scientific Review Board (SII-SRB) will review each proposal for:
1. Qualification of submission; if not approved the SII-SRB will contact you. Some applicants may receive additional questions to properly assess qualifications;
2. Qualification criteria include scientific rigor, clinical impact, feasibility, ethics, and overall alignment with Sysmex Inostics priorities.*
20 finalists will be contacted and announced publicly by May 31, 2023.
All qualified non-finalists will be entered to win one $250 Amazon Gift card.
Finalists will be asked to submit additional details about their research.
After thorough evaluation of submissions from the 20 finalists, TWO winners will be announced by June 30, 2023.
The 18 runners-up will be offered a 10% discount on PSS sample processing to complete the work they submitted.

*Qualitative & quantitative award criteria can be found here.

To be eligible, your organization:

MUST be located within the United States;
MUST NOT be sponsoring a current a Sysmex Inostics (Inc or GmBH) project;
MUST execute a RESEARCH COLLABORATION AGREEMENT with Sysmex Inostics.
All specimens submitted for the study:
- Should NOT exceed 40 PSS SAMPLE RUNS;
- Must be received NO LATER than 11:59pm EST on December 31, 2023;
- Will become property of Sysmex Inostics and any residual specimens after analysis will be used for future internal applications;
For COMPLETE OFFICIAL CONTEST RULES, click here;
To APPLY, click here.

ASSAY	GENE CONTENT	SAMPLE TYPE	SENSITIVITY	INTENDED USE	ASSOCIATED DISEASES
BC-SEQ	AKT1, ERBB2, ESR1, KRAS, PIK3CA, TP53	Plasma or Buffy Coat (whole blood cells) from Streck cfDNA BCT or EDTA tubes	Detects down to 0.03% mutant allele frequency (MAF)	Therapy selection and monitor treatment response. This assay can also be used for adjudication of suspected non-tumor CHIP/Germline mutations.	Breast cancer, Uterine cancer, Endometrial cancer, Meningioma and Penile cancer
RAS-RAF-SEQ	AKT1, BRAF, KRAS, NRAS, PIK3CA3	Plasma or Buffy Coat (whole blood cells) from Streck cfDNA BCT tubes	Detects down to 0.03% mutant allele frequency (MAF)	Therapy selection, monitor treatment response and disease dynamics. This assay can also be used for adjudication of suspected non-tumor CHIP/Germline mutations.	Colorectal cancer, Melanoma, Non-small cell lung cancer, Multiple Myeloma and Pancreatic cancer